HOME >> BIOLOGY >> NEWS
Data in New England Journal of Medicine show benefits of REMICADE in ulcerative colitis patients

HORSHAM, Pa., and KENILWORTH, N.J., December 8, 2005 Landmark studies published today in The New England Journal of Medicine demonstrate the benefits of treatment with REMICADE (infliximab) in patients with ulcerative colitis (UC).

At week 8, in both the 54-week ACT 1 trial and the 30-week ACT 2 trial, statistically significant differences in the proportion of patients in clinical response, clinical remission, and with mucosal healing were shown in UC patients treated with REMICADE versus those receiving placebo. In particular, approximately two-thirds of UC patients treated with REMICADE achieved the primary endpoint of clinical response, defined as improvement in signs and symptoms. Moreover, more than half had mucosal healing and more than one-third were in clinical remission. Furthermore, in both ACT 1 and ACT 2, nearly one-quarter of REMICADE patients receiving corticosteroids at baseline were in remission and steroid-free by week 30. In both ACT 1 and ACT 2, a significantly greater proportion of patients treated with REMICADE compared with placebo achieved clinical response, clinical remission, and mucosal healing from week 8 through the end of each trial (week 54 in ACT 1 and week 30 in ACT 2).

A major advance in the treatment of UC, REMICADE is the first and only biologic indicated in the United States for reducing signs and symptoms, achieving clinical remission and mucosal healing, and eliminating corticosteroid use in patients with moderately-to-severely active UC who have had an inadequate response to conventional therapy. This approval was based on the 30-week data from both trials.

"These long term results highlight the benefits of REMICADE for the treatment of UC," said William J. Sandborn, MD, professor of medicine, Mayo Clinic College of Medicine, head of the Inflammatory Bowel Disease (IBD) Interest Group, director of the IBD Clinical Research Unit at Mayo Medical Center, and lead study investigator. "These data
'"/>

Contact: Michael Parks
215-325-4010
Centocor, Inc.
8-Dec-2005


Page: 1 2 3 4

Related biology news :

1. The New England Journal of Medicine reports data on eculizumab for the treatment of PNH
2. Manomet report studies impact of massive turnover of timberland in New Englands Northern Forest
3. Avian flu in perspective: New England Journal article reviews spectacular findings
4. Recent breakthroughs in common adult leukemia highlighted in New England Journal of Medicine
5. Stretching the supply of flu vaccine: Solution offered in new SLU research in New England Journal
6. News tips from the Journal of Neuroscience
7. News tips from the Journal of Neuroscience
8. News tips from the Journal of Neuroscience
9. News tips from the Journal of Neuroscience
10. Tips from the Journals of the American Society for Microbiology
11. Journalists can register now for ECCO 14 -- the European Cancer Conference

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... ... ... Regenative Labs has received approval from the Centers for Medicare & Medicaid Services ... jelly allografts to be assigned a Q code and be approved for application directly ... allograft product to be recognized as a 361 HCT/P by CMS regulated under 21CFR ...
(Date:7/22/2020)... ... July 21, 2020 , ... ... and innovation in technology and compliance, announces a new solution to manage regulated ... ensure every layer of their technology stack complies with FDA and global regulations. ...
(Date:7/10/2020)... ... ... Today CJ BIO announced the first in a series of Food Ingredient ... that is revolutionizing ingredient mixes, nutritional content and flavor profiles across a range of ... 2020 at11:00 AM (CDT) during SHIFT20, the virtual edition of the IFT Annual Meeting ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... (PRWEB) , ... July 29, 2020 , ... ... that can combine up to three different materials for use with CRM, neurostimulation, ... up to three materials to meet specific design requirements, performance, and cost criteria; ...
(Date:7/31/2020)... ... 2020 , ... The SDX® Respiratory Gating System , ... reached its 20th anniversary of worldwide use. Introduced in the US over the ... University of Pennsylvania, University of Michigan, University of Maryland, University of California San ...
(Date:7/18/2020)... ... ... After research model surgery and catheter implantation, the long journey of catheter ... of a successful study, while protecting and accessing the catheter or device post-surgery is ... from Envigo in a live webinar on Wednesday, August 5, ...
(Date:7/18/2020)... ... 17, 2020 , ... dicentra , a leading Contract ... industries, is pleased to announce that Charles Galea has joined its clinical trials ... is an accomplished and results-driven sales executive with over 10 years of expertise ...
Breaking Biology Technology:
Cached News: